Research programme: small molecule therapeutics - Bayer HealthCare Pharmaceuticals/Ligon Discovery
Alternative Names: SMM technology platformLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Bayer Schering Pharma; Ligon Discovery
- Developer Ligon Discovery
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
- 30 Sep 2010 Early research in Undefined indication in USA (unspecified route)